Lupin and Zydus to co-market saroglitazar

7 November 2023

Indian drugmakers Lupin (BSE: 500257) and Zydus Lifesciences (NYSE: ZYDUSLIFE) have entered into a licensing and supply agreement to co-market, saroglitazar Mg for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in India.

With a once daily, 4mg dose regimen, saroglitazar Mg enables better compliance, reduces pill burden, and offers greater convenience for patients, the companies pointed out.

Under the terms of this agreement, Lupin will have semi-exclusive rights to co-market the product in India under the brand name Linvas. Zydus, which gained regulatory approval from India’s Drug Controller General of India (DCGI) in December 2020, launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Lupin will pay Zydus undisclosed upfront licensing fees and milestone payments based on the achievement of pre-defined milestones.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK